BioLargo, Inc.

BioLargo reported Q1 2023 revenue of $3.742 million, up 288% year over year. Management said net loss improved roughly 68%-75% year over year to about $475,000, and cash was $643,264 versus $302.2 thousand a year ago. Environmental revenue was up 491% year over year and 86% versus Q4 2022. The company said SG&A was relatively static and operating cash flow was very close to breakeven. Forward-looking commentary pointed to continued Pooph growth, with partners forecasting about 20% quarter-over-quarter growth for the next year, and management expecting Clyra revenue increases in Q2 or Q3.

Dennis Calvert’s tone was highly optimistic and confidence-building, with repeated emphasis that BioLargo is becoming a “new company” with multiple commercialization paths. He highlighted Pooph as the immediate revenue driver, Clyra as a high-margin future opportunity, PFAS as a major long-term market, and the sodium-sulfur battery as potentially the largest revenue asset in the portfolio. He also stressed that the company is leaning on partnerships and staying lean until contracts justify added overhead.

No formal CFO remarks were given; management commentary covered the financials. Calvert said net loss was about $475,000, down roughly 75% from a year ago, and most of that loss was noncash. He said SG&A was “pretty static,” operating cash use was very close to positive, and cash stood at $643,264 versus $302.2 thousand a year earlier. He also noted net shareholder equity of $3.55 million and said the company has retired prior toxic debt, with only a few SBA/PPP items in dispute and a 3% SBA loan remaining.

Analysts asked about Clyra’s regulatory status, timing for revenue recognition, and distribution through hospital systems. Management said Bioclynse already has the needed regulatory approvals and expects revenue increases in Q2 or Q3, though hospital formulary and purchasing processes can take 90 days to 9 months. They also asked about South America waste-to-energy, Ultra Safe Nuclear, MLD sales, AOS, CupriDyne/BKT, and Pooph-related expansion; management generally said these are progressing but delayed by customer timing, financing, or lengthy commercialization cycles.